Core Insights - NeurAxis, Inc. has been awarded a Veterans Affairs (VA) Federal Supply Schedule (FSS) contract effective December 1, 2025, establishing it as a federal contractor and providing a pathway into the VA health system, which serves nearly 7 million active patients annually [1][3] - The company's proprietary technology, IB-Stim, is an FDA-cleared percutaneous electrical nerve field stimulator for treating functional abdominal pain in patients aged 8 and older, addressing a significant unmet medical need in functional dyspepsia [2][4] - The VA contract is expected to support sustained commercial momentum for NeurAxis entering 2026, alongside broadening reimbursement and increasing clinical adoption [1][3] Company Overview - NeurAxis, Inc. focuses on neuromodulation therapies for chronic and debilitating conditions in both children and adults, with a commitment to advancing science and evidence-based medicine [4] - IB-Stim is the only FDA-cleared therapy for functional dyspepsia, highlighting its unique position in the market [2] - The company is planning to dedicate sales resources to the VA and scale efforts as utilization of IB-Stim grows, supported by a Category I CPT code effective January 1, 2026 [3]
NeurAxis Secures Veterans Affairs Federal Supply Schedule Contract, Broadening Access to More Patients with Functional Abdominal Pain